Professor Tim Shaw
Professor Tim Shaw is the Director of the Research in Implementation Science and eHealth Group (RISe) in the Faculty of Health Sciences at the University of Sydney. He is Health Systems Lead and Director of Workforce Capability in the Digital Health Cooperative Research Centre (CRC).
The current focus of Professor Shaw’s team is on how we use health data to impact on clinical decision making, quality improvement and professional development. He co-leads the strategic development of Digital Health at the University of Sydney and chairs the Digital Health and Informatics Network.
Tim has worked closely with organisations including Australian Digital health Agency, eHealth NSW, Australian Commission for Safety and Quality in Health Care, Cancer Australia, Health Education and Training Institute NSW, Cancer Institute NSW, WHO, Institute for Healthcare Improvement, International Society for Quality in Healthcare and Partners Healthcare.
Professor Graham Mann
Professor Graham Mann is an internationally renowned cancer geneticist and translational research scientist, specialising in the study of melanoma.
In collaboration with the Melanoma Institute Australia (MIA) Professor Mann helps lead a multidisciplinary melanoma research program across the University of Sydney, Macquarie University and at the QIMR Berghofer Medical Research Institute, funded by NHMRC Program and Centre for Research Excellence grants. He is Co-Director of the Centre for Cancer Research and heads the Melanoma Research Laboratory at the Westmead Institute for Medical Research. He leads the Australian Melanoma Genome Project, which has built the first comprehensive genomic map of mutations in melanoma.
Professor Mann is a founding member and principal investigator of the international melanoma genetics consortium GenoMEL. He is Chair of the University of Sydney Cancer Research Network.
Associate Professor Stephen Fuller
Dr Lynleigh Evans
Dr Evans is a Senior Medical Advisor in Cancer Services at WSLHD. Dr Evans has diverse experience in policy development, strategic planning, program implementation, and clinical practice improvement in the public, private and not-for-profit sectors both in Australia and overseas.
Previous roles include CEO, the Skin and Cancer Foundation; Executive Director, St George Hospital and Executive General Manager, MBF (now BUPA). She has also worked extensively in the development sector including as Director of a comprehensive health sector reform program in Tonga (5 years), and as Emerging Infectious Diseases Advisor in Indonesia (3 years). Lynleigh has an MBBS, PhD (Physiology) and an MBA all from the University of Sydney.
Professor Jacob George
Professor Jacob George AM is the Robert W Storr Chair of Hepatic Medicine, Sydney Medical School; Director, Storr Liver Centre, The Westmead Institute for Medical Research; Head, Department of Gastroenterology & Hepatology, Westmead Hospital and Western Sydney Local Health District – Obesity-related Liver Disease and Cancer Group.
A renowned hepatologist and liver research scientist, Professor George studies the causes of and mechanisms for the development of liver disease and liver cancer. He contributes to investigator-initiated and multicentre international clinical trials on therapeutics for liver diseases, and leads a program of research on viral hepatitis, fatty liver disease, liver fibrosis, host genetics/liver immunology and the epidemiology, prevention and management of liver cancer. His research has a strong translational component, linking laboratory and clinical research. His team first identified the role of interferon lambda 3 gene polymorphisms for predicting treatment response in chronic hepatitis C, and a second gene polymorphism that interacts with interferon lambda 3. These discoveries are considered major advances in the field and the finest examples of ‘personalised medicine’.
Professor George was an author on the ground-breaking study of combination telaprevir, pegylated interferon and ribavirin therapy for hepatitis C, which changed the landscape of hepatitis C treatments, heralding the era of direct-acting antivirals. His work identifying insulin resistance as the universal underlying pathophysiological abnormality in fatty liver disease underpins the majority of research on this condition and is the cornerstone of current therapy (lifestyle intervention; exercise; insulin-sensitising agents). He also first described the association between hepatitis C and insulin resistance. Professor George is an advisor to Hepatitis Australia, the Transfusion Related AIDS and Infectious Diseases Service, and at state and national levels, on viral hepatitis. He oversees research for the Asian Pacific Association for the Study of Liver and is a Fellow of the American Association for the Study of Liver Disease.
Dr Peter Flynn
Dr Peter Flynn is Executive Medical Director of Nepean Hospital, and a specialist thoracic surgeon with over 25 years of experience in the surgical management of lung cancer, and provides the procedural support for all unresectable lung cancer patients.
Dr Flynn and his team are committed to the introduction of new approaches to improve patient care. In recent years he has been the driving force introducing new technologies into routine practice in the Nepean Lung Cancer MDT of which he is the Lead Clinician. In addition to its clinical service role, this group has played a major role in training Registrars from a number of specialties in lung cancer management as well as the MDT approach to cancer care.
Peter Flynn has taken an active role in developing the MDT model through involvement of the lung MDT in research projects and by adopting new measures into the MDT such as involving students in data collection and analysis during meetings. He has been a key driver of the Nepean Cancer Research Biobank.
Professor Golo Ahlenstiel
Professor Golo Ahlenstiel is Chair of Medicine at Blacktown Mount Druitt Hospitals, Western Sydney University. He heads the Blacktown Clinical Research Unit and the Liver research program at Blacktown Hospital & Clinical School. He chairs the bariatric research program that studies all aspects of obesity-related health issues as well as using basic science approaches to understand its pathogenesis.
Professor Ahlenstiel also heads the Immunology Group at Storr Liver Centre at the Westmead Institute for Medical Research with a focus on innate immunity in liver and gut as well as drivers of inflammation in chronic liver and gastrointestinal disease.